Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781245 | 0.90 | PIK3CG (0.74) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL4185207 | 0.90 | PIK3CG (0.74) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL4178088 | 0.82 | PIK3CD (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL27781229 | 0.82 | PIK3CD (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL1879400 | 0.82 | PIK3CD (0.60) | PIK3CGPIK3CDLMNA | |
| SCHEMBL12005581 | 0.81 | PIK3CG (0.62) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL27781353 | 0.80 | PIK3CG (0.61) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL4172105 | 0.80 | PIK3CG (0.61) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL1881522 | 0.80 | PIK3CD (0.67) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL3661401 | 0.80 | LMNA (0.60) | PIK3CGPIK3CDLMNASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CG 9/4885PIK3CD 8/4885LMNA 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.